Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept

Journal of Drugs in Dermatology

Volumn 9, Issue 1, 2010, Pages 68-70

  Kennedy, Jeremy Scott ^a   Devillez, Richard L ^a   Henning, Jeffrey Scott ^a  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MINOCYCLINE; PREDNISONE; ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CASE REPORT; DISEASE DURATION; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; HUMAN; MONOTHERAPY; MUCOUS MEMBRANE PEMPHIGOID; REMISSION; TREATMENT FAILURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG RESISTANCE; FACE; GINGIVA; MIDDLE AGED; PALATE; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; DERMATOLOGIC AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FACE; FEMALE; GINGIVA; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PALATE; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; RECEPTORS, TUMOR NECROSIS FACTOR; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77449141584     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid. Arch Dermatol. 2002;138:370-379.
2. Fleming TE, Korman NJ. Cicatricial Pemphigoid. J Am Acad Dermatol. 2000;43:571-591.
3. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with Etanercept in three patients. Arch Dermatol. 2006;142:1457-1461. (Pubitemid 44790639)
4. Sacher C, Rubbert A, Konig C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol. 2002;46:113-115. (Pubitemid 34073488)
5. Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with Infliximab. Arch Dermatol. 2006;142:1268-1270. (Pubitemid 44583275)
6. Prey S, Robert PY, Drouet M, et al. Treatment of ocular cicatricial pemphigoid with the tumor necrosis factor alpha antagonist Etanercept. Acta Dermato-Venereologica. 2007;87:74-94.
7. John H, Whallett A, Quinlan M. Successful biologic treatment of ocular mucous mem-brane pemphigoid with anti-TNF alpha. Eye. 2007;21:1434-1435. (Pubitemid 350066484)
8. Gubinelli E, Bergamo F, Didona B; et al. Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol. 2005;55:1107-1108. (Pubitemid 44716495)
9. Lee SJ, Li Z, Sherman B, Foster CS. Serum levels of tumor necrosis factor alpha and in-terleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1993;34:3522-3525. (Pubitemid 24011987)
10. D'Auria L, Mussi A, Bonifati C, Mastroianni A. Increased serum IL- 6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid; Relationships with disease activity. J Eur Acad Dermatol Venereol. 1999:12:11-15. (Pubitemid 29132980)
11. Ameglio F, D'Auria L, Bonifati C, et al. Cytokine pattern in blister fluid and serum of pa-tients with bullous pemphigoid: Relationships with disease intensity. Br J Dermatol 1998;139:611-614. (Pubitemid 28212243)
12. Feliciani C, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol. 2000;114:1-7.
13. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol. 2003;49(2 Suppl): S105-S111. (Pubitemid 36951254)
14. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita. Arch Dermatol. 2002;138:380-384. (Pubitemid 34226336)
15. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2005;296-302. (Pubitemid 44491079)
16. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Der-matol. 2003;139:1051-1059. (Pubitemid 36994832)
17. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conven-tional immunosuppressive therapy regimens in patients with severe oral pemphigoid. Arch Dermatol. 2001;137:1181-1189.
18. Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid sparing agent. J Am Acad Dermatol. 2001;45:256-259. (Pubitemid 32729310)
19. Hall VC, Liesegang TJ, Kostick DA, Lookingbill DP. Ocular mucous membrane pem-phigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol. 2003;139:1083-1084. (Pubitemid 36994841)